The expansion of chondrocytes in automated bioreactors for clinical use requires that a relevant number of cells be generated, starting from variable initial seeding densities in one passage and using autologous serum. We investigated whether the growth factor combination transforming growth factor beta 1/fibroblast growth factor 2/platelet-derived growth factor BB (TFP), recently shown to enhance the proliferation capacity of human articular chondrocytes (HACs), allows the efficiency of chondrocyte use to be increased at different seeding densities and percentages of human serum (HS). HACs were seeded at 1,000, 5,000, and 10,000 cells/cm 2 in medium containing 10% fetal bovine serum or 10,000 cells/cm 2 with 1%, 5%, or 10%HS. The chondrogenic capacity of post-expanded HACs was then assessed in pellet cultures. Expansion with TFP allowed a sufficient number of HACs to be obtained in one passage even at the lowest seeding density and HS percentage and variability in cartilage-forming capacity of HACs expanded under the different conditions to be reduced. Instead, larger variations and insufficient yields were found in the absence of TFP. By allowing large numbers of cells to be obtained, starting from a wide range of initial seeding densities and HS percentages, the use of TFP may represent a viable solution for the efficient expansion of HACs and addresses constraints of automated clinical bioreactor systems.
INTRODUCTION
A RTICULAR CARTILAGE has a limited capacity for selfrepair, and if left untreated, cartilage defects can lead to the early onset of osteoarthritic degenerative changes. Promising approaches to induce cartilage repair are based on the implantation of autologous chondrocytes directly after expansion 1 or after loading and culture on specific scaffolds.
and concentration in a defined medium volume. 6 However, in a bioreactor system like ACTES, cells have to be expanded in only one passage, and because of the fixed area of the culture surface and the variable size of cartilage biopsies, the initial cell seeding densities may be highly variable between production batches. Moreover, the system should use human autologous serum at low percentages, to avoid use of animal-derived factors and to reduce the dependence of the culture on a non-standardized factor such as autologous serum. With these constraints, the bioreactor system should yield at least 12 million chondrocytes, because typical autologous chondrocyte implantation is indicated to treat cartilage defects up to 12 cm 2 in size by injection of at least 1 million cells per cm 2 defect. 7 With the ultimate goal of defining suitable operating conditions for systems like ACTES, in the present study we aimed at determining whether a clinically relevant number (!12 million) of human articular chondrocytes (HACs) can be generated in 1 passage starting from variable initial seeding densities and using low percentages of human serum, assuming a culture surface area of 250 cm 2 , currently in use in the ACTES system. Specific growth factors, namely transforming growth factor beta 1 (TGFb-1), fibroblast growth factor 2 (FGF-2), and platelet-derived growth factor type BB (PDGF-BB) (TFP), previously shown to increase the proliferation efficiency of HACs, 8, 9 were tested to reduce the variability in the yield of HACs under the different conditions. Because the quality of HAC expansion is related not only to the number but also to the cartilag-forming capacity of the expanded cells, HACs grown under the different experimental conditions were assessed in a micromass pellet culture model typically used to investigate the chondrogenic capacity of various cells types.
10,11

MATERIALS AND METHODS
Human serum
Pools of human serum (HS) were purchased by Blutspendezentrum SRK Bern AG, and serum from 3 healthy donors was isolated from Blutzentrum, University Hospital Basel, Basel, Switzerland. The sera were aliquoted and stored at À208C until ready for use. Heat inactivation of the sera was not performed.
Cartilage sample collection and cell isolation
Full-thickness human articular cartilage biopsies were obtained postmortem (within 24 h after death) from the lateral condyle of knee joints of 5 individuals (mean age 42.7, range 27-61) with no history of joint disease, after informed consent by relatives and in accordance with the local ethics committee of University Hospital Basel, Switzerland. The biopsies used, although they were not derived from a traumatic joint, would be relevant for our target clinical application (e.g., treatment of cartilage injuries), considering the established similarity between chondrocytes surrounding a cartilage defect or from normal cartilage.
12 Cartilage tissues were minced and then digested with 0.15% type II collagenase (10 mL solution/g tissue, 300 U/mg, Worthington Biochemical Corporation, Lakewood, NJ) for 22 h, and the isolated chondrocytes were then seeded and expanded as described below.
Cell expansion
Cell seeding at different densities. Freshly isolated HACs were seeded at 1,000, 5,000 or 10,000 cells/cm 2 with Dulbecco's modified Eagle medium (DMEM) containing 4.5 mg/mL D-glucose, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, 100 mM N-2-hydroxyethylpiperazine-N 0 -2-ethanesulfonic acid buffer, 100 U/mL penicillin, 100 mg/ mL streptomycin, and 0.29 mg/mL L-glutamate (basic medium) supplemented with 10% fetal bovine serum (FBS) without (CTR) or with the addition of growth factors (1 ng/mL TGFb1, 5 ng/mL FGF-2, and 10 ng/mL PDGF-BB) (TFP) 13 and expanded in monolayer for 1 passage in a humidified 378C/5% carbon dioxide (CO 2 ) incubator. Medium was changed twice a week.
The densities 1,000 cells/cm 2 and 5,000 cells/cm 2 were used considering the size of a cartilage biopsy usually provided from patients undergoing autologous chondrocyte implantation (100-500 mg), 7 a normal yield after tissue digestion (2.6Â10 6 cells/g) 14 and the available cell expansion surface in ACTES system (250 cm 2 ), 6 whereas 10,000 cells/ cm 2 was considered to be a standard cell-seeding density. 13, 15 When HACs reached confluence, they were rinsed with phosphate buffered saline, detached by treatment with 0.3% type II collagenase, followed by 0.05% trypsin/0.53 mM ethylenediamine tetraacetic acid (EDTA), counted, and used to generate pellets as described below.
Use of different percentages of human serum. Freshly isolated HACs were seeded at 10,000 cells/cm 2 with basic medium supplemented with 1%, 5%, or 10% HS without or with supplementation of the growth factor combination TFP and expanded in monolayer for 1 passage in a humidified 378C/5% CO 2 incubator. Cells from 1 additional individual (male, 51 years old) were also cultured with 1%, 5%, or 10% serum obtained from 3 different donors.
Three-dimensional pellet cultures
To assess the quality of the expanded chondrocytes, HACs were induced to re-differentiate in pellet cultures as previously described. 8 Briefly, HAC were suspended in basic medium supplemented with ITS þ 1 (Sigma Chemical, St. Louis, MO; i.e., 10 mg/mL insulin, 5.5 mg/mL transferrin, 5 ng/mL selenium, 0.5 mg/mL bovine serum albumin, 4.7 mg/mL linoleic acid), 0.1 mM ascorbic acid 2-phosphate, 1.25 mg/mL human serum albumin, 10 À7 M dexamethasone and 10 ng/mL TGF-b1 (chondrogenic medium). Aliquots of 5Â10 5 cells/0.5 mL were centrifuged at 250 g for 5 min in 1228 FRANCIOLI ET AL.
1.5-mL polypropylene conical tubes (Sarstedt, Nümbrecht, Germany) to form pellets, which were placed onto an orbital shaker (Bioblock Scientific, Frenkendor, Switzerland) at 30 rpm. Pellets were cultured for 2 weeks, with medium changes twice per week, and subsequently processed for histological, immunohistochemical, and biochemical analysis as described below. Each analysis was performed independently on at least 2 entire pellets for each primary culture and expansion condition.
Analytical methods
Proliferation rate. Proliferation rate was calculated as the ratio of log 2 (N/N 0 ) to T, where N 0 and N are the numbers of cells respectively at the beginning and end of the expansion phase, log 2 (N/N 0 ) is the number of cell doublings, and T is the time required for the expansion.
Histological and Immunohistochemical analysis. Pellets were fixed in 4% formalin for 24 h at 48C, embedded in paraffin, cross-sectioned (5 mm thick), and stained with Safranin O for sulfated glycosaminoglycans (GAGs). Sections were also processed for immunohistochemistry to visualize collagen type II (II-II6B3, Hybridoma Bank, University of Iowa, Iowa City, IA), as previously described. 16 Biochemical analysis. Pellets were digested with protease K (0.5 mL of 1 mg/mL protease K in 50 mM Tris with 1mM EDTA, 1 mM iodoacetamide, and 10 mg/mL pepstatin-A) for 15 h at 568C, as previously described. 17 GAG amounts were measured spectrophotometrically using dimethylmethylene blue, 18 with chondroitin sulfate as a standard, and normalized to the deoxyribonucleic acid (DNA) amounts, measured spectrofluorometrically using the CYQuant cell proliferation assay Kit (Molecular Probes, Eugene, OR) and with calf thymus DNA as a standard. GAG contents are reported as mg GAG/mg DNA.
Statistical analysis. All values are presented as means AE standard deviation of measurements from 4 to 5 independent experiments (with cells from the 4-5 different individuals). The coefficient of variation (standard deviation as a percentage of the mean), was used to assess the variability of a certain parameter under different culture conditions. Differences between experimental groups were assessed using Mann-Whitney tests and considered statistically significant at p < 0.05.
RESULTS
Cell seeding at different densities
Cell proliferation. This set of experiments was performed using medium containing 10% FBS.
In CTR medium, HACs seeded at 10,000 and 5,000 cells/ cm 2 proliferated at comparable rates. Cells reached confluence within 15 to 19 days of culture and underwent a similar number of doublings (2.2 and 2.9, respectively) ( Table 1) . Instead, HACs seeded at 1,000 cells/cm 2 required more than 3 weeks to reach confluence, and during this time they underwent 2.2-fold more doublings than cells seeded at the highest density (Table 1) . In general, a decrease in cell density paralleled enhanced HAC expansion; the total cell doublings were 4.8, 2.9, and 2.2 for cells seeded at the densities of 1,000, 5,000 and 10,000 cells/cm 2 , respectively (Table 1 ). In medium containing growth factors (TFP medium), at any seeding density, chondrocytes proliferated at a remarkably and significantly higher rate (up to 3.5-fold), reached confluence in a shorter time (up to 2.0-fold) and underwent more doublings (up to 1.9-fold) than HACs cultured in CTR medium ( Table 1) . As observed for cells cultured in CTR medium, doublings of HACs expanded with TFP increased by decreasing seeding density (7.6, 5.4, and 3.9 for the seeding densities of 1,000, 5,000 and 10,000 cells/cm 2 , respectively). Expansion with TFP resulted in reduced variability in the proliferation rates of HACs seeded at the different seeding densities, with the coefficient of variation decreasing from 27.5 to 14.6.
We then used the doublings measured under the different conditions to estimate the number of HACs that would be obtained if chondrocytes were seeded in the culture surface of the ACTES system (equal to 250 cm 2 ). The required number for clinical-scale expansion (12 million cells) would not HAC were seeded in monolayer at different densities in medium containing 10% fetal bovine serum and cultured without growth factors (CTR) or with transforming growth factor beta 1, fibroblast growth factor 2, and platelet-derived growth factor type BB (TFP) for 1 passage. 
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be reached for any of the seeding densities in CTR medium, whereas expansion with TFP would yield more than 40 millions of cells for each seeding density condition (Fig. 1A) .
Chondrogenic capacity. Because not only the number of cells obtained after expansion, but also their quality, is a clinically relevant issue, we evaluated the chondrogenic capacity of cells expanded in the different conditions in a pellet culture model. HACs seeded at 10,000 and 5,000 cells/cm 2 produced tissues that stained similarly with Safranin O, whereas cells seeded at 1,000 cells/cm 2 generated pellets with a lower staining intensity (Fig. 2A) . Biochemical analysis of the pellets confirm this trend, although because of the large donor-to-donor variability, no statistically significant difference in the GAG contents of the generated tissues could be measured between the experimental conditions. Expansion with TFP reduced the variability in the GAG contents of pellets produced by cells seeded at different densities histologically and biochemically, with the coefficient of variation for the GAG/DNA contents decreasing from 37.5% to 24.5% (Fig. 2B) .
Cell expansion using different percentages of HS Cell proliferation. This set of experiments was performed using an initial seeding density of 10,000 cells/cm 2 .
In CTR medium, HACs cultured with 10% and 5% HS proliferated at comparable rates. Cells reached confluence within 9.5 to 10.5 days of culture and underwent a similar number of doublings (2.5 and 2.1, respectively) ( Table 2) . However, cells expanded with 1% HS required more time to reach confluence (1.4-fold) and underwent fewer doublings (2.1-fold) than chondrocytes cultured with 10% HS (Table  2 ). Chondrocytes displayed a higher proliferation rate overall (1.9-fold) when cultured with 10% HS than with 10% FBS (see Table 1 and 2).
In TFP medium, HACs cultured at any HS percentage proliferated at a higher rate than those cultured in CTR medium, although because of large donor-to-donor variability, statistical significance was established only for the lowest serum concentration. At 1% HS, TFP-expanded chondrocytes reached confluence in a shorter time (1.6-fold) and underwent more doublings (2.3-fold) than CTR-expanded cells (Table 2) . Expansion with TFP resulted in less variability in the proliferation rates of HACs cultured with the different In CTR medium, cells cultured with 1% HS would not yield the required number of cells (12 million) if cultured under the same conditions in the culture surface of the ACTES system (250 cm 2 ), whereas in TFP medium, more then 20 million chondrocytes would be generated for each HS percentage (Fig. 1B) .
Chondrogenic capacity. HACs expanded in CTR medium with 10% and 5% HS produced tissues similarly stained with Safranin O, whereas cells expanded with 1% HS generated pellets with a lower staining intensity (Fig. 3A) . Biochemical analysis of the pellets confirmed this trend, but because of the large donor-to-donor variability, no statistically significant difference in the GAG contents of the generated tissues could be established between the experimental conditions. Expansion with TFP reduced variability in the GAG contents of pellets produced by cells cultured with different HS percentages, with coefficient of variation decreasing from 11.6% to 4.4% (Fig. 3B) . Tissues that contained large amounts of GAG generally contained higher amounts of collagen type II protein, as assessed using immunohistochemical staining (Fig. 3C) .
To determine whether HS from different donors could promote cell proliferation and re-differentiation capacity differently, chondrocytes from 1 additional cartilage biopsy were expanded in TFP medium with serum obtained from 3 different donors and then cultured in pellets. For each HS percentage condition used (1%, 5%, and 10%), cells proliferated at similar rates (coefficient of variation < 6.0). However, a greater percentage of HS used during the expansion resulted in enhanced variability in the GAG contents of pellets generated by cells expanded with serum from different donors, with the coefficients of variation of 4.7, 19.5, and 46.1 for 1%, 5%, and 10% HS, respectively (Fig. 4) .
DISCUSSION
With the final goal of validating culture conditions for clinical-scale expansion of HACs, we investigated the proliferation capacity of HACs cultured starting from a wide range of initial seeding densities (1,000, 5,000, and 10,000 cells/cm 2 ) and HS percentages (1%, 5%, and 10%) in medium not supplemented and supplemented with growth factors. We found that expansion with CTR medium was not reproducible and did not yield a clinically relevant number of chondrocytes (!12 millions) at each seeding density condition and at the lowest percentage of HS. Using TFP medium, instead, proliferation capacity was strongly enhanced such that 22 to 55 million chondrocytes could be generated in the different experimental conditions tested. Moreover, medium supplementation with TFP reduced variability in proliferation and cartilage-forming capacity of cells expanded under the different experimental conditions.
In clinical practice, the dimension of a cartilage biopsy and therefore the number of chondrocytes available for ex vivo expansion will vary from donor to donor. Therefore, having the constraint of a fixed surface area, have initially evaluated the effect of seeding density on HAC proliferation capacity. To the best of our knowledge, this is the first study evaluating the growth capacity of articular chondrocytes of human origin at different initial seeding densities. Similar investigations have been performed using chondrocytes from nonarticular sites 19, 20 or of animal origin. 21 Our results indicate that HACs seeded at decreasing densities proliferated in CTR medium with greater rates, such that a maximum number of population doublings (4.8) was measured for HACs seeded at 1,000 cells/cm 2 . Mandl et al. observed a similar relationship between initial seeding density and proliferation capacity with human auricular chondrocytes. 20 The authors reported that, using a density of 3,500 or 7,500 cells/cm 2 , a 20-fold increase in cell number was reached between passage 2 and 3 for most donors. We have demonstrated that human articular chondrocytes seeded at 1,000 cells/cm 2 undergo almost 8 doublings (corresponding to more than a 250-fold increase in cell number) in less than 2 weeks in just 1 passage while maintaining their differentiation capacity, but only in the presence of TFP. Thus, the use of TFP during HAC expansion allows a clinically relevant number of cells to be obtained also if initially seeded at low densities (and therefore starting from a cartilage biopsy of small size), reduces the time required for cell expansion, and reduces the HACs were seeded in monolayer at 10,000 cells/cm 2 and cultured with different HS concentrations in medium without growth factors (CTR) or with transforming growth factor beta 1, fibroblast growth factor 2, and platelet-derived growth factor type BB (TFP) for 1 passage. For the calculation of the parameter, see the Materials and Methods section. Results are means AE standard deviations of values from 4 independent donor cell populations. *p < 0.05 from 10% HS; 8p < 0.05 from CTR.
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variability in proliferation rates of cells initially seeded at different densities. TFP-expanded chondrocytes generated pellets with high GAG contents even if they underwent a much larger number of doublings than cells expanded without growth factors. With the prospective of a clinical application, contact of human cells with FBS must be minimized, because proteins from ruminant materials have been implicated in prion transmission, 22, 23 and European legislation does not recommend their use. In the second part of our study, we therefore evaluated the effect of using HS on HAC proliferation capacity. Our observation that 10% of a pool of HS supported higher proliferation of chondrocytes than 10% FBS is in agreement with previous results obtained using autologous HS [24] [25] [26] and may be due to the higher concentration of epidermal-derived growth factor and PDGF measured in human serum. 25 Using an initial cell seeding density of 10,000 cells/cm 2 , we then showed that HAC expansion with TFP, but not with CTR medium, yielded more than 20 million cells for any HS percentage. Because the proliferation rate of HACs was higher using lower cellseeding densities (Table 1) , it is likely that TFP will allow the required cell numbers to be obtained for any HS percentage even at the lowest seeding densities, although this remains to be experimentally determined. When HS from different donors was used, similar and low coefficients of variation in HAC proliferation rate were measured at any HS percentage, whereas coefficients of variation in the GAG content of resulting pellets were dramatically greater with HS percentage. This result confirms the importance of assessing not only chondrocyte yields but also their chondrogenic capacity and also indicates the need for a reduction in the percentage of HS used to increase reproducibility of HAC quality. In this context, the use of TFP during HAC expansion, by supporting sufficient cell yields even at low percentages of HS, could also contribute to reducing the variability in the number and quality of expanded autologous chondrocytes.
From a regulatory standpoint, the use of recombinant growth factors for the production of a therapeutic product requires the appropriate level of qualification. Safety concerns related to the use of TFP during HAC expansion should have minor relevance, because extensive washing of the cell preparation will remove these components so that they would be virtually absent in the final graft material. However, chondrocyte populations generated using TFP might need to be further analyzed for specific genetic alterations possibly related to senescence or DNA methylation before their clinical use.
In conclusion, our study showed that the use of TFP represents a viable solution for the reproducible and efficient clinical-scale expansion of HACs. Although our findings were based on the use of conventional tissue culture plates, implementation of the principle would be particularly relevant for automated processing systems for clinical use, which have higher constraints than typical manual culture in dishes. The concept of using specific growth factors in clinical-grade bioreactors could be applied for the propagation of cells from different human sources to reduce variability in the number and quality of expanded cells and, ultimately, in the clinical outcome of cell-based regenerative techniques.
